Muse Capital invests in Evvy
Funding Provisional 84% confidence first seen
Evvy (Allora Health Inc.) closed a $40 million Series B round, with Muse Capital participating as a new investor. The funding was described as being used to validate new AI-enabled diagnostic and care models, starting with fertility-focused care, to scale its precision women’s health platform. The report also ties the investment to Evvy’s clinical claims, including higher diagnostic accuracy and reduced recurrence for conditions such as bacterial vaginosis.
The deal
Evvy $40M Series B · announced 15 Sep 2026
Investors Alumni Ventures Catalio Capital Management
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Evvy closed a $40 million Series B round, with Muse Capital participating as a new investor. According to the coverage, Evvy plans to use the funding to validate new AI-enabled diagnostic and care models, beginning with fertility-focused care, and to scale its precision women’s health platform.
- Why it matters
- For leaders evaluating women’s health or AI-enabled care markets, this financing gives Evvy more capacity to turn its current diagnostic platform into broader care offerings, which could strengthen its competitive position in fertility and adjacent clinical pathways. The reported clinical results cited in the coverage—high diagnosis rates in symptomatic patients and lower recurrence for bacterial vaginosis—make the company more relevant to partnership, product, and market-entry decisions, but those claims still need to be weighed against independent validation.
- Evidence
- The information comes from a single SiliconANGLE report stating that Evvy raised $40 million to scale its precision diagnostics and care platform and to validate new AI-enabled models starting with fertility care. The same report attributes to Evvy claims of diagnosing more than 90% of symptomatic patients and reducing recurrence of conditions such as bacterial vaginosis by 50%, with no independent corroboration cited in the provided coverage.
- What remains uncertain
- The coverage does not specify Evvy’s valuation, the size of Muse Capital’s participation, the exact evidence behind the clinical performance claims, or the timeline and regulatory path for the new AI-enabled care models. It is also unclear from the provided reporting how much of the reported outcomes have been independently validated or reproduced outside Evvy’s own studies or operations.
- Monitor next
- Watch for published clinical validation data or regulatory/partner announcements tied to Evvy’s fertility-focused AI care models.
Analytical support, not advice — assumptions and open questions stated above.